Anixike Wart Corn Remover Pen

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the removal of common warts, corns, and plantar warts. Common warts are characterized by a rough, "cauliflower-like" surface and are easily recognizable. Plantar warts are specifically located on the soles of the feet, are tender to touch, and exhibit an interrupted footprint pattern.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be cleaned thoroughly prior to treatment. Following this, the wart must be soaked in warm water for 5 minutes to facilitate the removal process. After soaking, the area should be dried completely.

The wart removal pen should be taken out, and the switch twisted to allow the medication to flow out. The medication should then be applied directly to the affected area. It is important to allow the medication to dry completely after application.

Treatment may be repeated once or twice daily as needed. This regimen should be continued for a duration of 10 to 12 weeks, or until the wart is completely removed.

Contraindications

Use of this product is contraindicated in the following situations:

Application is not recommended on irritated skin or any area that is infected or reddened, as this may exacerbate the condition. The product should not be applied to moles, birthmarks, warts with hair growth, genital warts, or warts located on the face or mucous membranes due to the potential for adverse reactions.

Additionally, individuals with diabetes or poor blood circulation should avoid using this product, as these conditions may increase the risk of complications.

Contact with the eyes must be avoided. In the event of exposure, the eyes should be flushed with water for 15 minutes.

Warnings and Precautions

For external use only. This product is contraindicated for application on irritated skin or any area that is infected or reddened. It should not be used on moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes. Caution is advised for individuals with diabetes or poor blood circulation, as these conditions may increase the risk of adverse effects.

In the event of accidental ingestion, immediate medical assistance should be sought by contacting the Poison Control Center at 1-800-222-1222.

Users are advised to discontinue use and consult a healthcare professional if discomfort persists.

Side Effects

For external use only. Patients are advised to stop use and consult a doctor if discomfort persists. This recommendation is crucial to ensure safety and address any potential underlying issues that may arise during treatment.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Anixike Wart Corn Remover Pen (salicylic acid 17% wart corn remover pen). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center (1-800-222-1222) should be contacted without delay.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

The available data regarding the use of salicylic acid during pregnancy is limited, as no specific information is provided in the prescribing information. There are no contraindications or risks associated with the use of salicylic acid during pregnancy mentioned in the insert. Additionally, no dosage modifications are specified for pregnant individuals, and there are no special precautions outlined for the use of this product in pregnant patients.

Healthcare professionals should consider the lack of data when advising women of childbearing potential and weigh the potential benefits against any unknown risks.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or its effects on lactation. Additionally, no data are provided concerning the excretion of this medication in breast milk or its potential effects on breastfed infants. Healthcare professionals should consider the lack of information when advising lactating mothers about the use of this medication.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

There is currently no specific information available regarding overdosage for this medication. Healthcare professionals are advised to monitor patients closely for any unusual symptoms or adverse effects that may arise. In the event of suspected overdosage, it is recommended to initiate supportive care and symptomatic treatment as necessary.

Healthcare providers should consider contacting a poison control center or a medical toxicologist for guidance on management strategies tailored to the individual case. Continuous assessment of the patient's clinical status is essential to ensure appropriate interventions are implemented promptly.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

Skin discoloration has been reported in postmarketing experience, occurring during or after the use of the product. These events were documented through voluntary reports and surveillance programs.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact the Poison Control Center at 1-800-222-1222 if the product is swallowed. It is important for patients to understand the seriousness of this action and to act promptly.

Patients should be instructed to discontinue use and consult a doctor if they experience persistent discomfort after using the product. This guidance is crucial for ensuring patient safety and addressing any potential adverse effects.

Additionally, healthcare providers should emphasize the importance of avoiding contact with the eyes. In the event that the product does come into contact with the eyes, patients should be advised to flush the eyes with water for at least 15 minutes. It is essential to communicate that the product is non-edible and should be stored securely, with the cap tightly closed, at room temperature and away from heat sources.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at room temperature, ensuring that it is kept away from excessive heat, specifically temperatures exceeding 37°C (99°F). Proper storage conditions are crucial to maintain the integrity and efficacy of the product.

Additional Clinical Information

The medication is administered topically, with a recommended frequency of once or twice daily as needed. Treatment should continue for 10 to 12 weeks or until the wart is removed. There are no additional details available regarding laboratory tests, abuse information, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Anixike Wart Corn Remover Pen, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)